-
40 pharmaceutical and biological concept stocks rose by more than 10% during the year, focusing on medical devices, traditional Chinese medicine and other tracks
Time of Update: 2022-09-06
Among them, the net profit growth rate of Dongbao Biological is a focus on the whole industry chain of natural collagen enterprises, semi-annual report shows that in the first half of the year, the company continued to focus on the "collagen +" strategic layout, continue to increase the promotion of terminal series of new products listing, with foreign investment as the starting point, improve brand and channel construction, establish a three-dimensional sales promotion network, terminal business to achieve new breakthroughs.
-
The medical insurance flight inspection found that the phenomenon of exceeding the medical insurance payment limit and other phenomena collectively "checked the pulse" to find the problem
Time of Update: 2022-09-06
(Zuo Handi on the website of the Central Commission for Discipline Inspection and State Supervision Commission) "Urine sediment quantitative examination is usually suitable for patients with urology, nephrology, obstetrics and renal disease, but all the patients admitted to the hospital have done this examination.
-
The substitution of high-end imports of domestic pharmaceutical equipment has accelerated, and it has been shown in the performance of the head
Time of Update: 2022-09-06
In general, high-end has become the development direction of the biopharmaceutical equipment industry, and the enterprises represented by the head are expected to gradually break through the "card neck" link through continuous innovation and research and development, and accelerate import substitution with cost-effective advantages and tap more market space.
-
Under the accelerated fundraising and expansion of pharmaceutical equipment leading enterprises, the market competitiveness will continue to improve
Time of Update: 2022-09-06
In April, Canaan Technology also announced that it intends to invest 50 million yuan in its own funds to establish a wholly-owned subsidiary, Tianjin Canaan Biomedical Equipment Co.
-
The 2022 vaccine NRA assessment covers the entire regulatory chain
Time of Update: 2022-09-06
standard On August 23, 2022, the World Health Organization (WHO) announced that China has passed the assessment of the National Regulatory System (NRA) for vaccines .
standard On August 23, 2022, the World Health Organization (WHO) announced that China has passed the assessment of the National Regulatory System (NRA) for vaccines .
-
There is a consensus on off-label medication!
Time of Update: 2022-09-06
On August 25, the Shandong Pharmaceutical Association issued the "Shandong Province Expert Consensus on Drugs with Off-label Drugs (2022 Edition)" . Off- label drug use is common in actual clinical p
-
Traditional Chinese medicine continues to usher in the policy east wind, and the performance of most enterprises has grown significantly
Time of Update: 2022-09-06
Among them, from the performance point of view, as of August 24, 30 Chinese medicine listed companies in A shares have disclosed the first half of the performance report, of which 20 Chinese medicine listed companies have achieved a year-on-year increase in net profit attributable to the mother, accounting for more than 60%.
-
China's ophthalmic medical demand shows a continuous growth trend, the market size or more than 100 billion yuan
Time of Update: 2022-09-06
For example, according to the 2022 semi-annual report released by Xingqi Eye Medicine, in the first half of this year, the company's operating income increased by 29.
-
Are diabetes drugs the next profit growth point? Pharmaceutical companies are accelerating their efforts
Time of Update: 2022-09-06
The industry said that with the increase in the number of patients, the increase in per capita disposable income, and the expansion of diabetes drug indications and other factors, in recent years, China's diabetes drug market has shown a growing trend year by year.
-
What is the future situation of the pharmaceutical sector? In the industry: the bottom has a bottom, and the upper can be expected
Time of Update: 2022-09-06
This direction is conducive to the weakening of homogeneous competition among pharmaceutical companies, so that the industry's capital, technology, clinical and other resources are concentrated in the head of innovative enterprises, and the concentration of the entire innovative drug research and development industry is expected to increase.
-
There have been changes in the collection of proprietary Chinese medicines!
Time of Update: 2022-09-06
The time nodes of the purchase and sale agreement with the purchase and sale of pharmaceutical enterprises are as follows: Drugs On August 30, the Hunan Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of Centralized Procurement of Chinese Patent Medicines in Inter-Provincial Alliances" (hereinafter referred to as the "Notice"), announcing that the alliance will be launched on October 20.
-
BeiGene, Junshi Bio and other leading innovative pharmaceutical companies are more willing to invest in this
Time of Update: 2022-09-06
Some institutions have released research reports saying that with the commercial expansion of BeiGene's core products BTK inhibitors and PD-1 monoclonal antibodies, as well as the expected milestones in the second half of 2022 (including the approval of new indications), BeiGene's globalization process will be verified, and it will also feed back early research and development investment through higher sales revenue.
-
The market of 100 billion Chinese medicine formula granules has both opportunities and challenges!
Time of Update: 2022-08-30
With the acceleration of unified standard work and inter-provincial joint procurement, and the continuous release of policy dividends, the market space of traditional Chinese medicine formula granules is widely optimistic .
-
The China Securities Regulatory Commission approves the IPO registration of 3 pharmaceutical companies including Enwei Pharmaceuticals on the Growth Enterprise Market
Time of Update: 2022-08-30
, Ltd. Enwei Pharmaceutical plans to raise 700 million yuan to enhance the competitiveness of its main business Enwei Pharmaceutical was established in May 2005, mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs, etc.
-
The prospect of the pharmaceutical equipment market is improving, and the policy side and the demand side will continue to provide momentum for development
Time of Update: 2022-08-30
Policies and demands are providing continuous development impetus for the pharmaceutical equipment industry (Source: Pharmaceutical Network) Tofflon's 2022 semi-annual performance forecast shows that the net profit attributable to shareholders of listed companies during the reporting period was 391.
-
There are long-term investment opportunities in the pharmaceutical sector, and two high-growth tracks are optimistic
Time of Update: 2022-08-30
However, in the long run, the industry is generally optimistic about investment opportunities in the pharmaceutical sector, and there are two high-growth tracks worthy of attention, including innovative drugs and innovative medical devices .
-
Innovative drugs have been approved for listing one after another, and pharmaceutical companies are actively accelerating their commercialization
Time of Update: 2022-08-30
For example, Zai Lab said that in terms of commercialization exploration, the company actively cooperated with medical insurance negotiations on the one hand, and strived to allow more innovative treatments to benefit the majority of patients through medical insurance .
-
The third batch of centralized procurement in Zhejiang is on the way!
Time of Update: 2022-08-30
According to the data of Minenet, in 2020, the number of lansoprazole in urban public hospitals, counties and Among the terminal types of peptic ulcer medicines in public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), the sales of lansoprazole exceeded 3 billion yuan .
-
The tide of new shares breaking is intensifying, and the pharmaceutical and biological sector has become a "hardest hit area"
Time of Update: 2022-08-30
It is reported that Rendu Bio will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on March 30, 2022, with an issue price of 72.
-
Raised 3.2 billion!
Time of Update: 2022-08-30
2 billion yuan (including this amount), and after deducting the issuance costs, it is planned to be used to invest in the biopharmaceutical equipment industry trial production center project, Jiangsu Biomedical equipment industrialization base project, Zhejiang Tofflon Biotechnology Co.
